Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812174 | 0.87 | ELANE (0.45) | CTSKCTSSCTSLCTSB | |
| SCHEMBL1810398 | 0.86 | CTSK (0.44) | CTSKCTSSCTSL | |
| SCHEMBL28449915 | 0.82 | CTSK (0.46) | CTSKCTSSCTSLCTSB | |
| SCHEMBL1809949 | 0.81 | NPC1 (0.47) | CTSLCTSB | |
| SCHEMBL4634185 | 0.79 | NPC1 (0.44) | HPGD | |
| SCHEMBL7212770 | 0.78 | CTSK (0.46) | CTSKCTSSCTSLCTSB | |
| SCHEMBL7212869 | 0.78 | CTSK (0.46) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4633819 | 0.78 | TAS1R3 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL4634179 | 0.77 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL10004489 | 0.76 | RAB9A (0.49) | CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | NOS3 3106/4885NOS1 2801/4885NOS2 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.